Osimertinib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Osimertinib and local guidelines before prescribing.
Tyrosine kinase inhibitor
Mechanism
Third-generation EGFR tyrosine kinase inhibitor.
Uses
EGFR-mutant non-small-cell lung cancer.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Rash, diarrhoea, interstitial lung disease, QT prolongation, cardiomyopathy.
Interactions
CYP3A4 inducers reduce levels.
Contraindications and cautions
Interstitial lung disease
Monitoring
ECG, LVEF, FBC
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Caution in severe renal or hepatic impairment
Overdose and reversal
Supportive
Special advice
Check LVEF and QT; stop if ILD.
More from the textbook: uses, cautions and other points
- 2. A 52-year-old never-smoker has stage IV lung adenocarcinoma with an EGFR exon 19 deletion. Answer: First-line osimertinib (oral EGFR inhibitor) rather than chemotherapy or immunotherapy.
Respiratory: Lung Cancer - Osimertinib after surgery for EGFR-mutant disease.
Respiratory: Lung Cancer - Osimertinib | Oral EGFR inhibitor - advanced EGFR-mutant NSCLC, and adjuvant after surgery. Rash, diarrhoea, QT prolongation, rarely pneumonitis.
Respiratory: Lung Cancer - EGFR inhibitors (EGFR-mutant lung cancer - osimertinib): Acne-like rash, diarrhoea, paronychia, ILD.
Oncology: Principles - After surgery - adjuvant chemotherapy (stage II–III), targeted treatment (e.g. osimertinib for EGFR mutations), or immunotherapy; neoadjuvant chemo-immunotherapy in some.
Surgery: Cardiothoracic, neurosurgery and plastic surgery - EGFR | Erlotinib, gefitinib, osimertinib (small molecules); cetuximab (antibody) | EGFR-mutant lung cancer; RAS wild-type colorectal cancer
Cell Biology: Cell cycle, signalling, cell death and stem cells
Where it is discussed in the book
- Respiratory: Lung Cancer (3 mentions)
- Oncology: Principles (1 mention)
- Surgery: Cardiothoracic, neurosurgery and plastic surgery (1 mention)
- Integrated respiratory chapter (3 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)